-LRB-/O During/O its/O centennial/O year/O ,/O The/B-ORG Wall/I-ORG Street/I-ORG Journal/I-ORG will/O report/O events/O of/O the/O past/O century/O that/O stand/O as/O milestones/O of/O American/O business/O history/O ./O -RRB-/O
LUTHER/B-PERSON BURBANK/I-PERSON CROSS/O -/O BRED/O PLANTS/O to/O produce/O the/O billion/O -/O dollar/O Idaho/B-GPE potato/O ./O
Bioengineers/O set/O out/O to/O duplicate/O that/O feat/O --/O scientifically/O and/O commercially/O --/O with/O new/O life/O forms/O ./O
In/O 1953/O ,/O James/B-PERSON Watson/I-PERSON and/O his/O colleagues/O unlocked/O the/O double/O helix/O of/O DNA/O -LRB-/O deoxyribonucleic/O acid/O -RRB-/O ,/O the/O genetic/O key/O to/O heredity/O ./O
Twenty/O years/O later/O ,/O two/O California/B-GPE academics/O ,/O Stanley/B-PERSON Cohen/I-PERSON and/O Herbert/B-PERSON Boyer/I-PERSON ,/O made/O ``/O recombinant/O ''/O DNA/O ,/O transplanting/O a/O toad/O 's/O gene/O into/O bacteria/O ,/O which/O then/O reproduced/O toad/O genes/O ./O
When/O Boyer/B-PERSON met/O Robert/B-PERSON Swanson/I-PERSON ,/O an/O M.I.T./B-ORG -/O trained/O chemist/O -/O turned/O -/O entrepreneur/O in/O 1976/O ,/O they/O saw/O dollar/O signs/O ./O
With/O $/O 500/O apiece/O and/O an/O injection/O of/O outside/O capital/O ,/O they/O formed/O Genentech/B-ORG Inc/I-ORG ./O
Commercial/O gene/O -/O splicing/O was/O born/O ./O
Genentech/B-ORG 's/O first/O product/O ,/O a/O brain/O protein/O called/O somatostatin/O ,/O proved/O its/O technology/O ./O
The/O next/O to/O be/O cloned/O ,/O human/O insulin/O ,/O had/O market/O potential/O and/O Genentech/B-ORG licensed/O it/O to/O Eli/B-ORG Lilly/I-ORG ,/O which/O produced/O 80/O %/O of/O the/O insulin/O used/O by/O 1.5/O million/O U.S./B-GPE diabetics/O ./O
Their/O laboratory/O credentials/O established/O ,/O Boyer/B-PERSON and/O Swanson/B-PERSON headed/O for/O Wall/O Street/O in/O 1980/O ./O
At/O the/O time/O ,/O Genentech/B-ORG had/O only/O one/O profitable/O year/O behind/O it/O -LRB-/O a/O modest/O $/O 116,000/O on/O revenue/O of/O $/O 2.6/O million/O in/O 1979/O -RRB-/O and/O no/O product/O of/O its/O own/O on/O the/O market/O ./O
Nonetheless/O ,/O the/O $/O 36/O million/O issue/O they/O floated/O in/O 1980/O opened/O at/O $/O 35/O and/O leaped/O to/O $/O 89/O within/O 20/O minutes/O ./O
The/O trip/O from/O the/O test/O tube/O was/O not/O without/O snags/O ./O
Boyer/B-PERSON and/O Cohen/B-PERSON ,/O for/O instance/O ,/O both/O still/O university/O researchers/O ,/O had/O to/O be/O talked/O into/O applying/O for/O a/O patent/O on/O their/O gene/O -/O splicing/O technique/O --/O and/O then/O the/B-ORG Patent/I-ORG Office/I-ORG refused/O to/O grant/O it/O ./O
That/O judgment/O ,/O in/O turn/O ,/O was/O reversed/O by/O the/B-ORG U.S./I-ORG Supreme/I-ORG Court/I-ORG ,/O leaving/O Cohen/B-PERSON and/O Boyer/B-PERSON holding/O the/O first/O patents/O for/O making/O recombinant/O DNA/O -LRB-/O now/O assigned/O to/O their/O schools/O -RRB-/O ./O
Gene/O -/O splicing/O now/O is/O an/O integral/O part/O of/O the/O drug/O business/O ./O
Genentech/B-ORG 's/O 1988/O sales/O were/O $/O 335/O million/O ,/O both/O from/O licensing/O and/O its/O own/O products/O ./O
